ARTH sure looks like a pump and dump, now that you mention it. OTC. Not even one institutional as a major holder.
So you know what I think? I think I'm spinning my wheels by using it as a comparison.
You just cannot put a numbrer on it and you can't know what, if anything is priced in to DYSL due to Xcede.
You can't quantify it, but as a sharehioder, you still have to feel good about it ,as a sort of added bonus- maybe like buying a new car you like anyway and it also has a trunk full of lotto tickets.
CEO said, "It’s a wonderful opportunity" "What it ultimately will result in isn’t clear at this point but we all feel pretty good about it."
...IMO, if revs start coming in from iPeMS Ag, as explained by CEO.
From last CC,RE: iPeMS Ag product:
So we see tremendous amount of opportunity in this group and our vision and goal is that in a few years, this group really rival the other two businesses really getting to that level of revenue and operation and really contribute significantly to our overall operating income.
Q. Right, okay. As a shareholder, I’m definitely looking forward to that. Thank you. And then ... my final question is, you talked about recurring monthly revenue range from iPeMS Ag as being $5,000 to $100,000 a month, which is pretty significant. What were revenues in the quarter from those products if you had any?
A. Probably none in this quarter, we just announced our products, so we are now just acquiring these customers, so very little, really non-material. I would envision that by the end of the third quarter, we begin to seeing some of that revenue and then it gradually would expand.
IF/ When Revs begin to "rival the other two businesses" IMO, could go to the teens.
Share price could start climbing earlier than the timeframe I mentioned, IMO, if there are institutional buys or more insider buying before the timeframe.
Next CC (2Q, reporting next mo) we should get some reconfirmation that revs will begin appearing by end of 3Q (reporting around May). By 8-2015 we should get 4Q ER and price should respond nicely. I'm hoping for $3 or maybe even over $4.00.
Even if only a $100 or $200K comes in, price should still go up, IMO, because they are high margin, recurring revs, not dependent on government budgets, they would be coming from a new, high growth area with a potential for rapid widespread adoption and because the amount of $ they are investing in IPeMs should taper way off and stop being a drag on cash flow from operations.
ARTH has a cap of $13.8 today. If you gave me $13.8 and told me I had to buy either Xcede or ARTH I'd flip a coin because neither is proven yet. But then again the insiders put their own money into Xcede so I'd go with that.
If Xcede is worth $13.81M - the same as ARTH (with zero revs and a patent pending for " a novel approach to stop bleeding" ),it's absurd that DYSL with over $42M in revs and growing divisions, is valued at $22.59. That would mean DYSL could give XCEDE to a charity and the rest of the company is worth a bit over $8M. Something has to give here. You can't have ARTH as high as $13.8 or you can't have DYSL as low as $22.59.
DYSL(CEO ON BOWSERREPORT):I think the company is undervalued. We have no
cost for Xcede intellectual property, and we have no
significant costs for the 50 going on 100 patents. We
are also generating positive income and cash, with cash
reaching $3-3.5 million. The company just executed a
creative acquisition, only paying $500,000 in cash and
700,000 in shares. Management is doing things in a
creative, entrepreneurial way so that we can begin to
grow the operations of the company.
We are in the development stage and have generated no operating revenues to date and do not expect to do so in the foreseeable future due to the early stage nature of our current product candidates. We currently have no products that have obtained marketing approval in any jurisdiction, we have not generated revenues since inception, we had net losses for the year ended September 30, 2013 and for the six months ended March 31, 2014 of $1,853,791 and $9,188,596 respectively, and we had an accumulated deficit as of March 31, 2014 of $13,820,467. We are currently devoting substantially all of its efforts toward product research and development. As further discussed in "Liquidity and Capital Resources" below, we will need to raise substantial additional funds in order to continue operating our business
Xcede is not priced in
If it is one thing that bugs me on these message boards is how many people do not know the difference between the words "loose" and "lose".
IMO, that should be restated, at least to this:
If it is one thing that bugs me on these message boards, it is how many people do not know the difference between the words "loose" and "lose".
Or perhaps this: If there is one thing that bugs me on these message boards, it is how many people there are who post, yet they do not know the difference between the words "loose" and "lose".
Or maybe this is best: If there is one thing that bugs me on these message boards, it is the fact that many people do not know the difference between the words "loose" and "lose".
Those statements would be proper, gramatically, wouldn't they?
But not this: If it is one thing that bugs me on these message boards is how many people do not know the difference between the words "loose" and "lose".
But noone is perfect. Lol! Can't tell you how many times I've seen that one. I mean, it's two words, folks!! Does it look right as one word?
Their are many ways to bug people,lol. As many ways as their are people on message boards who can't get there, they're and their straight, lol...just kidding.
To, too and two are also confused a lot. Making unnecessarily long posts bugs people to, I suppose. Lol, I meant "too". And don't get me started about starting a sentence with "and" or about the difference between "well" and "good".
All due respect to fellow posters; apostrophes, commas,spelling, typos and grammar aside, MITK seems to be headed up today! No time to proofread.Or is that proof read? Proof-read?How about read and red. Anyone red so far?
There are no specific plans to acquire anything that I know of. The divestiture does not mean they changed their overall strategy for growth. That strategy still includes acquisitions. Before the divestiture they couldn;t acquire but now they can. And we saw how quickly after DichroTec.This is from their FAQ on investor web page.
Dynasil plans to identify – and invest in – those products and technologies with the greatest revenue and growth potential in our markets.
To achieve that goal, the Company will focus on:
Building a strong team ... penetrate new markets and increase our presence in existing markets....enhancing our intellectual property estate through the filing of new patents...
Executing a focused acquisition strategy which complements our existing businesses.
Since 2004, Dynasil has made a successful transition from a single-product line optics company to a combined contract-research/commercial optics and photonics company focused on commercializing its own products, patenting its own innovations and advancing its own technologies. The initial acquisitions of Optometrics, Evaporated Metal Film and the Precision Optics Corporation filter line product enabled the Company to substantially increase revenue and profitability. This growth positioned Dynasil to make the acquisitions of RMD Research, its sister company RMD Instruments, Hilger Crystals, and Dynasil Biomedical, transactions which represent transformative opportunities for our Company.
Dynasil’s recent acquisition of vacuum coating chambers from DichroTec Thin Films LLC significantly increased our coating capacity. This allows our EMF subsidiary to consider large optic, film, fuel cell and heads up display opportunities not previously available to EMF. In addition, Dynasil’s RMD subsidiary has a proprietary process for manufacturing thin film scintillators for digital radiography. Such products can also be coated in these chambers.
Yes but DYSL does not own XCEDE entirely.I f it were to be sold, proceeds would go to other stakeholders too, I think.
I could see ARTH shares going to $.40 pretty quickly if they even announced Human Trials are ongoing. And a lot higher upon successful trials.So I could see that comparable doubling in value. We can speculate but the upshot is, there's a potential and unlocking it would be a catalyst for PPS.
Nothing we can do but wait:
In prepared remarks on last CC:
We are actively looking into creative financing options for this entity, which could include finding a way to spin it off to our shareholders. As previously disclosed, we are also in discussions with large biomedical companies about the technology, have expanded the management team, are actively recruiting additional expertise for the Xcede board, and are developing the protocols and the plan for first in human trials.
We are actively looking at ways to finance this such that we provide adequate liquidity into Xcede and we figure out a way to have it not necessarily affect Dynasil’s performance going forward and we figure out a way to get the ownership of it into the hands of our shareholders. It's not an easy solution to come up with, but we are working on some ways -- actively working on ways to try to do it.
So anyway, DYSL has a cap of $23.74M and revs of $42.31. Seems undervalued. Also, They have a history of making acquisitions that add to shareholder value. There'll be more because M&A is a part of their growth strategy.
Human tests should be 6 to 12 months away.
Some past quotes Re Excede: "we need to get additional funding in Xcede'[I think the just got some but there may be more]. "It’s a wonderful opportunity" "What it ultimately will result in isn’t clear at this point but we all feel pretty good about it."
"We’re talking to companies" and "whoever it is we likely partner with would be the company that would take that product through FDA approval and to the market".
I do not think that that amount is unattainable at some point along the post incubation period, if all keeps going well from a competitive standpoint and the product continues to satisfy a long list of design criteria and it proceeds with success of human trials.
Keep in mind the path ahead to the really huge money would be fraught with many obstacles, possible delays and pitfalls, I surmise. Also there are other players for sure:
"StartUps and Emerging Competitors in Surgical Sealants, Glues, and Hemostats
Medical Adhesive Revolution
DYSL's Xcede division is in talks with large biomedical companies regarding the patch tecnology, according to CEO's statements.
It may be somewhat tricky trying to cash in on this at this early stage. But be mindful, any profits from Xcede will be apportioned out to all the stakeholders including the Mayo investmant arm. I'm not sure how the pie will be sliced or at what point along the incubation period it may be spun out to DYSL shareholders.
The enterprise value of ARTH is $14.53M according to Yahoo Finance " key statistics". ARTH has a similar product already through pre clinical trials. They have zero sales.The value is based upon hope, at this point.
But J&J paid a huge sum for a comparable technology ,actually in use today. $448M.
IMO, Xcede is way better, if you read the patent app. J&J is building an entire plant in Ireland mainly to produce their sealant product.
This is a pretty big deal and the beauty is, we can participate in profits without all the debt associated with most biomed startups. DYSL has a diferent model.Unlike ARTH shareholders, we don't have to worry about huge burn rates.
My hope is there will be some upside. How much and when is the question in my mind.Could be a bunt single or bases loaded, game winning homer at any given time,IMO.
01/23/2015 | 08:50pm US/Eastern
Patent Issued for Bicycle Presence Detection in a Roadway Using Video Data Analytics
By a News Reporter-Staff News Editor at Information Technology Newsweekly -- Iteris, Inc. (Santa Ana, CA) has been issued patent number 8933818, according to news reporting originating out of Alexandria, Virginia, by VerticalNews editors.
This patent was filed on March 13, 2013 and was published online on January 13, 2015.
As farmers are increasingly under pressure to squeeze out
profits and comply with burdensome regulations, they
search relentlessly for operational efficiencies. To satisfy
this escalating demand, established agriculture and technology
companies and a host of startups are bringing
innovative products and services to the agriculture arena,
focused on helping farmers close that gap. This emerging
Precision agriculture is thought by many to be the biggest
technological change in agriculture since the introduction
of hydraulics in the 1940’s.
Advanced sensors and Big Data.
Weather and soil data
can be coupled with real time plant health data from
aerial imagery (satellites and the emergence of drones)
and on-the-ground sensors for in-depth analysis. This
analysis supports real time predictive decision-making
to drive lower costs and improved yields. Real time sensors,
mounted on fertilizer application equipment, allow
farmers to vary the application of fertilizer as the equipment
passes over the crops.
Return on investment realization. Increased functionality
and expanded offerings of precision agriculture
devices, integrated software, analytics, and cloud services
have improved potential ROI’s to farmers. Anecdotal
success stories are spreading through the agriculture
This growing awareness, coupled with the demographic
shift to younger, technologically-savvy farmers, has
many pundits predicting a dramatic increase in the rate
of growth of precision agriculture.
Current estimates show the size of the precision agriculture
market in the U.S. is between $1.5 and $2.0 billion1
It is estimated to grow in the U.S. over the next 5 years
at a 13% percent growth rate to reach $3.0 to $3.5 billion1
Many of these smaller [start up]companies will be bought as they
gain momentum and provide unique products and services
that larger companies can leverage into their current customer
Some interesting news regarding human trials
First I found this:
May 18 14
Xcede Technologies, Inc. Presents at 13th Annual MedTech Investing Conference, May-21-2014. Venue: Graves Hotel, 601 First Avenue North, Minneapolis, MN 55401, United States. Presentation Date & Speakers: May-21-2014, Allen J. Berning, Executive Director.http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=248337060
Then, going to the MedTech conference I found this:
Xcede is in the selection and approval process for first human trials with 2 European clinical research centers.
Spent quite a bit of time explaining exactly why I'm recently psyched about ITI.
The precision Ag market is for real and I say this- not only based on googling around- but I had some first hand encounters with people who happened to be at a hotel Agro convention while I was there on other matters and according to them it's the place to be.
Anyways, it's best to save posts when you include a link because Yahoo is heartless when it decides to delete.Poof!! Your work is gone.
"For 2014, three of our companies, Optometrics, EMF and Dynasil Fused Silica had record revenue results and Hilger had the largest revenue year under ourownership. This is a significant accomplishment, given our liquidity situation."
So the sale of the divisions results in lost revs. You have to do a bit of research to find that nearly all this lost rev has been offset by the growth in the remaining divisions. You can't just do a stock screen for growth in revs and come up with DYSL.
However, you cannot buy low and sell high if EVERYONE knows exactly how much the company is growing. So in this sense, it's good that it's disguised a bit by the divestiture.
Once they have some positive Q's behind them and the DichroTec deal shows some signs of paying off, I'm hoping they start to take the story on the road and do some investor presentations. That would seem to me, to be coming in 2015, but we'll see.
".5 million rev per quarter" Yes, correct.
According to Capt'n Sully, the goal is to squeeze "2-3 times current EMF" division's revenue revs with this single, fairly low cost acquisition. This will take a few years, if all goes as they plan. To keep it real, the expertise of the former owners couldn't seem to get Dichrotec to more than $2M a Yr. in revs, so we hope some synergies tilt things more favorably for the DYSL shareholders.
Just to get a feel for what Dynasil bought, you may want to check the pics on facebook. One is of a HUD in an automobile, which, as I ponted out, is a possible high growth area to address.
Dichrotec produced the special lighting for Dancing With The Stars and the 2012 London Olympics.
They are located in Rochester NY, home of Rochester Optical Manufacturing Co who had a PR about doing some of the HUD for Google Glass. So the field is interesting.
Hope it pays off, over time, for shareholders. A nice $1 or 2M manufacturing sub contracting from someone like Rochester Optical would be nice. Not sure if such a thing is remotely possible but I'm sure deals of some sort will be coming in, in time.
What it is, is large volume. In Rochester, you compete on price, quality and service. The Ithica plant, on the other hand, is about customization. Of couse, if the thin film job is for many items of particularly large size, Rochester has a sort of monopoly on being able to do that, because of the 96" chamber. Not too many places around the hemisphere can do that. Or so it is, I'm slowly learning.
Securing the L3 contract had to do with Dynasils patents for the desired product, I believe. This is an instance where the research hand fed the manufacturing hand. It's an affirmation of their companywide strategy. It's a sort of vertical integration of their past acquisitions, coming together to produce synergies and growth. This is from CC:
"Optometrics is now able to meet the current customer demand for this [patented] product and has the capacity to double production if demand increases."
So the possible inference is this: Dynasil chose to scale up beyond what is necessary to meet the contract. They scaled up to account for a double
Another higher margin, $3 or $4M in top line revs?
It's tanatalizing to even think about this. A combined total of $7 M in revs is about 30% of the entire market cap. PPS would HAVE to again explode.
However, to keep things grounded, the other deal, the Dichrotec deal, will dampen profits for the next report.
But again, looking beyond THAT bit of headwind means opening up to ANOTHER tanatalizing price appreciation catalyst:
Here's how the CEO put it:
"DichroTec was losing money and it will take us part of 2015
to turn it around. Hence we will incur an operational income loss during part of 2015 necessary to fix this operation.
We believe with this capacity [ i.e.,Dichrotec's 14, large coating chambers], we can grow this business to 2-3 times current EMF revenue over the next few years."
Look as I may, I'm unable to determine what EMF's revs are now but it's a sure bet that doubling or tripling them will be ANOTHER good thing for PPS.
“Farmers around the world are challenged to make key decisions for their farms in the face of increasingly volatile weather, as well as a proliferation of information sources,” ... “the ability to turn data into actionable insight and farm management recommendations is vitally important for agriculture around the world and can greatly benefit farmers, regardless of farm size or their preferred farming methods. Monsanto shares this important vision for our business and we look forward to creating even greater experiences for our farmer customers.”http://news.monsanto.com/press-release/corporate/monsanto-acquire-climate-corporation-combination-provide-farmers-broad-suite
Iteris's thoughts on Precision Ag( from SEC filing):
"through investments in research, development, sales, and marketing, we are entering into new commercial markets, in particular the agriculture industry, offering our ClearPath Ag hyper-local weather information solutions and we expect positive market acceptance in upcoming quarters."
Market cap is $55.35M. Cash is $22.39M. Receivables plus cash is $41.9.
They are cash flow positive. Lots of IP. Little downside. Risk to reward looks real good, imo. Book Value is $1.75/ share.
Iteris's Business Outlook statement on SEC
"we continue to remain cautious about our overall business."
"we are entering into new commercial markets, in particular the agriculture industry, offering our ClearPath Ag hyper-local weather information solutions and we expect positive market acceptance in upcoming quarters."
Jan. 21, 2015
"we see a wide array of opportunities moving forward"
Our 2014 acquisition of the assets of DichroTec Thin Films LLC significantly increased our optical coating capacity, opening up large optics, HUD and other markets to EMF.
A head-up display or heads-up display—also known as a HUD—is any transparent display that presents data without requiring users to look away from their usual viewpoints. The origin of the name stems from a pilot being able to view information with the head positioned "up" and looking forward, instead of angled down looking at lower instruments.
Although they were initially developed for military aviation, HUDs are now used in commercial aircraft, automobiles, computer gaming, and other applications.
Global Head-up Display Market to Surpass USD5 billion by 2019,The defense sector is expected to continue dominating the market due to increasing military spending, globally, coupled with growing demand for airplane, helicopter, land vehicles, etc. The automotive sector, which accounted for second largest market sharein 2013, in revenue terms, is also forecast to witness significant growth over the next 3-4 years. Moreover, the launch of affordable HUDs is anticipated to see the surge in demand for these devices in low and medium segment cars.